EP4043464A4 - Fused pyridone compound, and preparation method therefor and use thereof - Google Patents
Fused pyridone compound, and preparation method therefor and use thereof Download PDFInfo
- Publication number
- EP4043464A4 EP4043464A4 EP20865331.1A EP20865331A EP4043464A4 EP 4043464 A4 EP4043464 A4 EP 4043464A4 EP 20865331 A EP20865331 A EP 20865331A EP 4043464 A4 EP4043464 A4 EP 4043464A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- preparation
- method therefor
- pyridone compound
- fused
- fused pyridone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title 1
- -1 pyridone compound Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910892032 | 2019-09-20 | ||
| CN201911129688 | 2019-11-18 | ||
| CN201911157939 | 2019-11-22 | ||
| CN202010054188 | 2020-01-17 | ||
| CN202010102546 | 2020-02-19 | ||
| CN202010230303 | 2020-03-27 | ||
| CN202010306926 | 2020-04-17 | ||
| CN202010367694 | 2020-04-30 | ||
| CN202010967317 | 2020-09-15 | ||
| PCT/CN2020/116510 WO2021052499A1 (en) | 2019-09-20 | 2020-09-21 | Fused pyridone compound, and preparation method therefor and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP4043464A1 EP4043464A1 (en) | 2022-08-17 |
| EP4043464A4 true EP4043464A4 (en) | 2023-10-04 |
Family
ID=74883935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP20865331.1A Pending EP4043464A4 (en) | 2019-09-20 | 2020-09-21 | Fused pyridone compound, and preparation method therefor and use thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220389029A1 (en) |
| EP (1) | EP4043464A4 (en) |
| JP (1) | JP2022549171A (en) |
| KR (1) | KR20220086573A (en) |
| CN (2) | CN114728968A (en) |
| AU (1) | AU2020350745A1 (en) |
| BR (1) | BR112022005193A2 (en) |
| CA (1) | CA3155066A1 (en) |
| CL (1) | CL2022000666A1 (en) |
| CO (1) | CO2022004686A2 (en) |
| IL (1) | IL291467A (en) |
| MX (1) | MX2022003401A (en) |
| TW (1) | TWI761961B (en) |
| WO (1) | WO2021052499A1 (en) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019217307A1 (en) | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| EP3908283A4 (en) | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| MX2022002465A (en) | 2019-08-29 | 2022-05-19 | Mirati Therapeutics Inc | Kras g12d inhibitors. |
| CA3152025A1 (en) | 2019-09-24 | 2021-04-01 | David BRIERE | Combination therapies |
| MX2022005053A (en) | 2019-10-28 | 2022-05-18 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras g12c mutant. |
| EP4328229A2 (en) * | 2019-10-30 | 2024-02-28 | Genfleet Therapeutics (Shanghai) Inc. | Substituted heterocyclic fused cyclic compound, preparation method therefor and pharmaceutical use thereof |
| IL294048A (en) | 2019-12-20 | 2022-08-01 | Mirati Therapeutics Inc | Sos1 inhibitors |
| AU2021248363B2 (en) * | 2020-04-03 | 2024-02-15 | Medshine Discovery Inc. | Octahydropyrazinodiazanaphthyridine dione compounds |
| JP2023539188A (en) * | 2020-08-21 | 2023-09-13 | 浙江海正薬業股▲ふん▼有限公司 | Tetracyclic derivatives, their production methods and their pharmaceutical uses |
| CN116670136A (en) * | 2020-12-31 | 2023-08-29 | 正大天晴药业集团股份有限公司 | Tetracyclic compound and medical application thereof |
| TW202246267A (en) * | 2021-03-25 | 2022-12-01 | 大陸商上海濟煜醫藥科技有限公司 | Fused pyridone compound salt form and crystal form, and application thereof |
| CN115124533A (en) * | 2021-03-26 | 2022-09-30 | 浙江海正药业股份有限公司 | Tetracyclic derivative, preparation method and medical application thereof |
| CN116848111A (en) * | 2021-03-26 | 2023-10-03 | 浙江海正药业股份有限公司 | KRAS inhibitor key intermediate and preparation method thereof |
| CN116113632A (en) * | 2021-03-30 | 2023-05-12 | 浙江海正药业股份有限公司 | Heterocyclic derivative, preparation method and medical application thereof |
| WO2022223037A1 (en) * | 2021-04-22 | 2022-10-27 | 劲方医药科技(上海)有限公司 | Salt or polymorph of kras inhibitor |
| AU2022314009A1 (en) * | 2021-07-23 | 2024-01-25 | Suzhou Zanrong Pharma Limited | Kras g12d inhibitors and uses thereof |
| CN117222654A (en) * | 2021-09-06 | 2023-12-12 | 苏州赞荣医药科技有限公司 | KRAS G12C inhibitors and uses thereof |
| WO2023116895A1 (en) * | 2021-12-24 | 2023-06-29 | 劲方医药科技(上海)有限公司 | Polymorph of kras inhibitor, preparation method therefor, and use thereof |
| CN116327956A (en) * | 2022-04-01 | 2023-06-27 | 劲方医药科技(上海)有限公司 | Pharmaceutical composition, use thereof and method for treating cancer |
| WO2024081674A1 (en) | 2022-10-11 | 2024-04-18 | Aadi Bioscience, Inc. | Combination therapies for the treatment of cancer |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018217651A1 (en) * | 2017-05-22 | 2018-11-29 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| US20190177338A1 (en) * | 2017-12-08 | 2019-06-13 | Astrazeneca Ab | Chemical compounds |
| WO2020156285A1 (en) * | 2019-01-29 | 2020-08-06 | 博瑞生物医药（苏州）股份有限公司 | Benzopyridone heterocyclic compound and use thereof |
| WO2021083167A1 (en) * | 2019-10-30 | 2021-05-06 | 劲方医药科技(上海)有限公司 | Substituted heterocyclic fused cyclic compound, preparation method therefor and pharmaceutical use thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2016004360A (en) * | 2013-10-10 | 2016-08-19 | Araxes Pharma Llc | Inhibitors of kras g12c. |
| JO3556B1 (en) * | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | Combination therapies for treatment of cancer |
| KR20180005178A (en) * | 2015-04-10 | 2018-01-15 | 아락세스 파마 엘엘씨 | Substituted quinazoline compounds and methods for their use |
| WO2016168540A1 (en) * | 2015-04-15 | 2016-10-20 | Araxes Pharma Llc | Fused-tricyclic inhibitors of kras and methods of use thereof |
| WO2017100546A1 (en) * | 2015-12-09 | 2017-06-15 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
| US20200010479A1 (en) * | 2017-02-03 | 2020-01-09 | The University Of North Carolina At Chapel Hill | Inhibitors of microbial beta-glucuronidase enzymes and uses thereof |
| TW201906848A (en) * | 2017-05-11 | 2019-02-16 | 瑞典商阿斯特捷利康公司 | Chemical compound |
| CN111630053A (en) * | 2018-01-19 | 2020-09-04 | 南京明德新药研发有限公司 | Pyridinopyrimidine derivatives as KRASG12C mutant protein inhibitors |
| WO2019213516A1 (en) * | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| CN112300194B (en) * | 2019-07-30 | 2022-01-14 | 上海凌达生物医药有限公司 | Condensed ring pyridone compounds, preparation method and application |
-
2020
- 2020-09-21 KR KR1020227013103A patent/KR20220086573A/en active Search and Examination
- 2020-09-21 AU AU2020350745A patent/AU2020350745A1/en active Pending
- 2020-09-21 BR BR112022005193A patent/BR112022005193A2/en unknown
- 2020-09-21 US US17/761,983 patent/US20220389029A1/en active Pending
- 2020-09-21 WO PCT/CN2020/116510 patent/WO2021052499A1/en unknown
- 2020-09-21 TW TW109132517A patent/TWI761961B/en active
- 2020-09-21 CA CA3155066A patent/CA3155066A1/en active Pending
- 2020-09-21 CN CN202080078771.6A patent/CN114728968A/en active Pending
- 2020-09-21 CN CN202310905052.2A patent/CN116947885A/en active Pending
- 2020-09-21 EP EP20865331.1A patent/EP4043464A4/en active Pending
- 2020-09-21 MX MX2022003401A patent/MX2022003401A/en unknown
- 2020-09-21 JP JP2022517446A patent/JP2022549171A/en active Pending
-
2022
- 2022-03-17 IL IL291467A patent/IL291467A/en unknown
- 2022-03-18 CL CL2022000666A patent/CL2022000666A1/en unknown
- 2022-04-12 CO CONC2022/0004686A patent/CO2022004686A2/en unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018217651A1 (en) * | 2017-05-22 | 2018-11-29 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| US20190177338A1 (en) * | 2017-12-08 | 2019-06-13 | Astrazeneca Ab | Chemical compounds |
| WO2020156285A1 (en) * | 2019-01-29 | 2020-08-06 | 博瑞生物医药（苏州）股份有限公司 | Benzopyridone heterocyclic compound and use thereof |
| EP3919483A1 (en) * | 2019-01-29 | 2021-12-08 | Brightgene Bio-medical Technology Co., Ltd. | Benzopyridone heterocyclic compound and use thereof |
| WO2021083167A1 (en) * | 2019-10-30 | 2021-05-06 | 劲方医药科技(上海)有限公司 | Substituted heterocyclic fused cyclic compound, preparation method therefor and pharmaceutical use thereof |
| EP4053118A1 (en) * | 2019-10-30 | 2022-09-07 | Genfleet Therapeutics (Shanghai) Inc. | Substituted heterocyclic fused cyclic compound, preparation method therefor and pharmaceutical use thereof |
Non-Patent Citations (2)
| Title |
|---|
| BETHANY HALFORD: "Amgen unveils its KRas covalent inhibitor AMG 510", CHEMICAL & ENGINEERING NEWS, vol. 97, no. 14, 8 April 2019 (2019-04-08), pages 4 - 4, XP055694388, DOI: 10.1021/cen-09714-scicon1 * |
| See also references of WO2021052499A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020350745A1 (en) | 2022-04-07 |
| CA3155066A1 (en) | 2021-03-25 |
| CN116947885A (en) | 2023-10-27 |
| KR20220086573A (en) | 2022-06-23 |
| CN114728968A (en) | 2022-07-08 |
| TWI761961B (en) | 2022-04-21 |
| TW202126654A (en) | 2021-07-16 |
| CL2022000666A1 (en) | 2022-10-14 |
| WO2021052499A1 (en) | 2021-03-25 |
| US20220389029A1 (en) | 2022-12-08 |
| JP2022549171A (en) | 2022-11-24 |
| MX2022003401A (en) | 2022-07-13 |
| BR112022005193A2 (en) | 2022-08-16 |
| EP4043464A1 (en) | 2022-08-17 |
| IL291467A (en) | 2022-05-01 |
| CO2022004686A2 (en) | 2022-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4043464A4 (en) | Fused pyridone compound, and preparation method therefor and use thereof | |
| EP4011886A4 (en) | Tetracyclic compound, preparation method therefor and use thereof | |
| EP3972967A4 (en) | Heterocyclic compounds, preparation methods and uses thereof | |
| EP4077311A4 (en) | Heterocyclic compounds, preparation methods and uses thereof | |
| EP3889154A4 (en) | Heterocyclic compound intermediate, preparation method therefor and application thereof | |
| EP4053118A4 (en) | Substituted heterocyclic fused cyclic compound, preparation method therefor and pharmaceutical use thereof | |
| EP4043437A4 (en) | Pyridine oxynitride, preparation method therefor and use thereof | |
| EP4039706A4 (en) | Cldn18.2-targeting antibody, preparation method therefor, and use thereof | |
| EP4015520A4 (en) | Oxygen-containing heterocyclic compound, preparation method and application thereof | |
| EP3967687A4 (en) | Substituted phenylpropenylpyridine derivative, and preparation method therefor and medical use thereof | |
| EP3916862A4 (en) | Current collector, preparation method therefor and application thereof | |
| EP3929185A4 (en) | Nitrogen-containing fused cyclic compound, preparation method therefor and use thereof | |
| EP3964504A4 (en) | Benzothiophene compound, preparation method therefor and use thereof | |
| EP4008715A4 (en) | Halogen substituted compound, and preparation method therefor and application thereof | |
| EP4082534A4 (en) | Solid preparation, and preparation method therefor and use thereof | |
| EP3604343A4 (en) | Fusion protein, preparation method therefor and use thereof | |
| EP3812377A4 (en) | Brivaracetam intermediate, preparation method therefor, and preparation method for brivaracetam | |
| EP3858833A4 (en) | Aminonordecane derivative, and preparation method therefor and application thereof | |
| EP3828169A4 (en) | Dication compound, preparation method therefor and use thereof | |
| EP3808751A4 (en) | Camptothecin derivative, preparation method therefor and application thereof | |
| EP3777894A4 (en) | Brain-targeting, long-acting protein conjugate, preparation method therefor, and composition comprising same | |
| EP3978482A4 (en) | Isoxazoline compound, preparation method therefor and application thereof | |
| EP4063453A4 (en) | Polypropylene composition, preparation method therefor and use thereof | |
| EP3998263A4 (en) | Tricyclic compound, preparation method therefor and use thereof | |
| EP3909967A4 (en) | Steroid compound, and use thereof and preparation method therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20220413 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| TPAC | Observations filed by third parties |
Free format text: ORIGINAL CODE: EPIDOSNTIPA |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20230904 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/4745 20060101ALI20230829BHEP Ipc: A61K 31/506 20060101ALI20230829BHEP Ipc: A61K 31/5383 20060101ALI20230829BHEP Ipc: A61K 31/4985 20060101ALI20230829BHEP Ipc: A61K 31/542 20060101ALI20230829BHEP Ipc: A61K 31/5365 20060101ALI20230829BHEP Ipc: A61P 35/00 20060101ALI20230829BHEP Ipc: C07D 513/22 20060101ALI20230829BHEP Ipc: C07D 498/22 20060101ALI20230829BHEP Ipc: C07D 498/14 20060101ALI20230829BHEP Ipc: C07D 471/22 20060101ALI20230829BHEP Ipc: C07D 471/14 20060101AFI20230829BHEP |